Biomarin Pharmaceutical (BMRN) Net Income towards Common Stockholders (2009 - 2026)

Biomarin Pharmaceutical's Net Income towards Common Stockholders history runs 18 years deep, the most recent figure standing at $105.5 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 43.17% year-over-year to $105.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $268.7 million (down 48.7% YoY) and the FY2025 annual result came in at $348.9 million, down 18.26% from the prior year.
• Net Income towards Common Stockholders was $105.5 million for Q1 2026 at Biomarin Pharmaceutical, up from -$46.6 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $240.5 million in Q2 2025 and bottomed at -$46.6 million in Q4 2025.
• A 5-year average of $70.0 million and a median of $56.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders soared 8282.73% — and 2025, when it sank 137.28%.
• Biomarin Pharmaceutical's Net Income towards Common Stockholders stood at -$249000.0 in 2022, then surged by 8282.73% to $20.4 million in 2023, then soared by 513.22% to $124.9 million in 2024, then sank by 137.28% to -$46.6 million in 2025, then surged by 326.58% to $105.5 million in 2026.
• Business Quant data shows BMRN's Net Income towards Common Stockholders at $105.5 million in Q1 2026, -$46.6 million in Q4 2025, and -$30.7 million in Q3 2025.